Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

BioMérieux on Wednesday reported sales growth of approximately 5 percent for the first half of 2022 compared to the first half of 2021.

On August 30, Merck announced that the new indication for its nine-valent human papillomavirus vaccine (brewer's yeast) (hereinafter referred to as "nine-valent HPV vaccine") has been approved by National Medical Products Administration.

Thermo Fisher Scientific said on Tuesday that it has received CE-IVD marking for its Oncomine Dx Express Test, a next-generation sequencing tumor mutation profiling test, and the companion Oncomine Reporter Dx analysis software and has launched them.

T2 Biosystems announced Tuesday it has regained compliance with the Nasdaq's minimum market value of listed securities continued listing requirement.

On August 26, Dian Diagnostics achieved operating income of CNY 10.753 billion, an increase of 85.68% over the same period last year; net profit attributable to the parent was CNY 1.880 billion, an increase of 158.54% over the same period last year.

Canadian firm Genomadix has entered into a collaboration with the Mayo Clinic to advance its point-of-care molecular analyzer technology.

Chinese sequencing tech company MGI Tech, a BGI affiliate, plans to go public this week in an initial public offering in China, targeting proceeds of CNY 2.53 billion (approximately $366.4 million based on Monday's exchange rate).

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. obtained the CE extension certificate issued by TüV SüD, a famous EU notified body under the IVDR regulations.

A new UC San Francisco study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment.

Myriad Genetics said Friday that Japan's Ministry of Health, Labor, and Welfare has granted expanded coverage for the firm's BRACAnalysis test as a companion diagnostic to identify patients with early-stage